-
Outlook Therapeutics NASDAQ:OTLK Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD.
Location: 485 Route 1 South, Building F, Suite 320, New Jersey, 08830, United States | Website: outlooktherapeutics.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
34.76M
Cash
32.02M
Avg Qtr Burn
-16.14M
Short % of Float
30.54%
Insider Ownership
35.58%
Institutional Own.
35.63%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Eye disease , Wet age-related macular degeneration | BLA Resubmission | |
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Wet age-related macular degeneration , Eye disease | BLA Submission | |
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Eye disease | Phase 3 Initiation | |
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Diabetes, Eye disease , BK virus, Adenovirus, Epstein-Barr virus, Human herpesvirus 6, Cytomegalovirus, Diabetic macular edema | Phase 3 Initiation |